Cochlear Bone Anchored Solutions AB (“Cochlear”) owns U.S. Patent No. 7,043,040 (“the ‘040 patent”), directed to a hearing aid for use in those with unilateral hearing loss. Oticon Medical AB, etc. (“Oticon”) successfully petitioned for inter partes review (IPR) of all claims of the ‘040 patent, and in those reviews the USPTO Patent and Trial Appeal Board (“PTAB” or “Board”) held claims 4-6 and 11-12 unpatentable, but maintained the validity of claims 7-10. Cochlear appealed the PTAB’s decision with respect to claims 4-6 and 11-12, while Oticon cross-appealed the PTAB’s determination in connection with claims 7-10. The Federal Circuit (Newman, O’Malley and Taranto) affirmed, but for claim 10, on which they vacated and remanded to the PTAB for further action.
- Will SCOTUS Tell Bad Spaniels to Roll Over?
- DOJ Takes Key Step Toward Breaking Up Big Tech with Antitrust Complaint Against Google
- Federal Circuit Rejects St. Jude’s Challenge to Validity of Snyders’ Heart Valve Patent
- CAFC Affirms District Court Dismissal of Declaratory Judgment Under Doctrine of ‘Abstention’
- Federal Circuit Affirms PTAB Finding that Immunex Antibody Patent is Obvious
- American Innovators Express Support for Recent and Proposed Changes in Patent System
- This Week in Washington IP: Senate Commerce Committee to Grill Tech CEOs on Section 230, House Big Tech Antitrust Report and USPTO’s Quarterly TPAC Meeting
- Determining the Likelihood that an AI Patent Application Will Be Allowed at the USPTO
- Examining Samsung’s and LG’s LCD Patent Portfolios Following Decisions to Halt LCD Production
- Types of Subsequent Patent Applications in the United States (Part II)